The discussion around SAS vs R in clinical trials is often framed as a technology debate. In practice, sponsors need a more operational question: what programming environment will support reliable analysis, compliant processes, reproducible results, efficient delivery, and regulatory confidence for this study or program?

SAS has been the dominant language in clinical trial statistical programming for decades. It is deeply embedded in many sponsor environments, CRO processes, legacy programs, validation frameworks, and submission workflows. R, meanwhile, has gained significant momentum due to its statistical flexibility, open-source ecosystem, visualization capabilities, reproducible research tools, and increasing use in pharma.
For sponsors, this is not a simple replacement question. It is a strategy question.

Why SAS remains strong in clinical trials?

SAS is widely used in clinical programming because it is established, familiar to regulators and industry teams, and well integrated into long-standing submission processes. Many organizations have validated SAS environments, standardized macros, established QC workflows, and experienced programming teams.
SAS is particularly common for:

• SDTM and ADaM programming.
• Tables, figures, and listings.
• ISS and ISE integrations.
• Legacy study conversions.
• Submission-ready programming.
• Regulated production workflows.
• Standardized QC and validation environments.
• The strength of SAS is not only the language. It is the ecosystem of processes, talent, validation practices, and historical regulatory experience around it.

Why R adoption is increasing?

R for clinical trials has become increasingly important because it offers powerful statistical methods, strong graphics, modern reporting tools, and a large open-source ecosystem. It is especially attractive for exploratory analysis, simulations, Bayesian modeling, data visualization, Shiny applications, reproducible reporting, and advanced statistical workflows.

R is also gaining traction in production and submission-related contexts.

Industry collaborations such as the R Consortium R Submissions Working Group have been developing public examples and pilot packages that support R submission to FDA reviewers, demonstrating how these workflows can be implemented in practice.Still, using R in regulated clinical programming requires more than writing correct code. It requires an operational framework that addresses package management, validation, reproducibility, documentation, quality control, version control, and environment control.

FDA submission strategy: language is only one part of the question

Regulatory agencies are generally concerned with whether the submitted results are reliable, reproducible, traceable, and adequately documented. The programming language is only one part of that picture.
For sponsors considering R in submission-related workflows, key questions include:

• Is the programming environment controlled and documented?
• Are package versions traceable?
• Can analyses be reproduced by another qualified reviewer or team?
• Are programs and outputs quality-controlled?
• Are dependencies documented and available?
• Is there a validation strategy for open-source packages?
• Can the submission package be reviewed efficiently?
• Does the ADRG explain the programming environment clearly?
• These questions are not unique to R. They apply to any programming environment. However, they become more visible when sponsors move beyond legacy SAS-only processes.

Validation and reproducibility

Validation in clinical programming does not mean every line of code is certified by an external authority. It means the sponsor has a controlled process that demonstrates that systems, tools, programs, and outputs are fit for their intended use.
For SAS, many organizations already have mature validation frameworks. For R, sponsors may need to define or strengthen processes for:

• Package qualification.
• Version control.
• Dependency management.
• Reproducible environments.
• Code review.
• Independent QC.
• Output comparison.
• Documentation of known limitations.
• Audit trails and change control.

The objective is not to make R behave exactly like SAS. The objective is to ensure that R-based workflows meet the same expectations for reliability, traceability, and reviewability.

Where hybrid SAS and R strategies make sense?

Many sponsors are not choosing between SAS and R as an all-or-nothing decision. Hybrid strategies are increasingly common.
For example, SAS may remain the primary production environment for SDTM, ADaM, and TFLs, while R is used for simulations, advanced statistical modeling, visualization, exploratory analyses, or internal dashboards. In other cases, R may be used for production analyses where the sponsor has a validated framework and appropriate documentation.
A hybrid approach can be practical, but it requires governance. Without clear standards, hybrid programming can create inconsistency, duplicated effort, and QC complexity.
A strong hybrid strategy should define:

• Which language is used for which purpose?
• How outputs are quality-controlled?
• How programming environments are validated?
• How packages and dependencies are managed?
• How code is reviewed?
• How documentation is captured?
• How results are reproduced?

The sponsor decision framework

Before selecting SAS, R, or a hybrid model, sponsors should assess the study and program context.
Important factors include:

• Regulatory submission plans.
• Existing sponsor standards.
• CRO or vendor capabilities.
• Internal programming expertise.
• Complexity of statistical methods.
• Need for visualization or interactive tools.
• Integrated summary requirements.
• Legacy study data.
• Long-term maintenance needs.
• Budget and timelines.
• Quality management expectations.

The best language strategy is the one that supports the study’s scientific and regulatory objectives with the least avoidable operational risk.

Common mistakes in the SAS vs R debate

Sponsors can run into problems when the debate becomes ideological rather than practical.
Common mistakes include:

• Choosing R because it is modern without building the required governance.
• Staying with SAS by default even when R would better support simulations or visualization.
• Using both languages without clear ownership and QC rules.
• Underestimating package and dependency management.
• Treating exploratory code as if it were production code.
• Failing to document the programming environment for review.
• Ignoring internal team skill sets.
• The issue is rarely the language alone. It is the operating model around the language.

How Bioforum Supports SAS/R Programming Strategy?

Bioforum supports statistical programming across SAS, R-related workflows, CDISC standards, SDTM, ADaM, TFLs, ISS and ISE integrations, and submission-ready programming. Our focus is on fit-for-purpose programming strategy, quality control, reproducibility, and regulatory readiness.
Bioforum’s JetConvert technology also reflects our broader approach to modernizing programming workflows while maintaining expert oversight and quality. Technology can accelerate delivery, but submission confidence still depends on strong specifications, traceability, validation, and independent review.

Operational Readiness, Not Old vs. New

SAS vs R in clinical trials should not be treated as a question of old versus new. It is a question of operational readiness.SAS remains deeply established in clinical trial submissions. R is increasingly valuable and increasingly feasible in regulated environments when supported by the right controls. Hybrid strategies can be powerful, but only when governance, QC, documentation, and reproducibility are clearly defined.
For sponsors, the strongest programming strategy is the one that supports reliable data, transparent analysis, efficient review, and sustainable delivery across the clinical program.

Ready to Strengthen Your Programming Strategy?

Evaluating your statistical programming strategy or preparing submission-ready outputs? Bioforum helps sponsors implement reliable, traceable, and quality-controlled programming workflows across CDISC datasets, TFLs, integrated summaries, and regulatory documentation.